Overstappen op aflibercept bij patiënten die niet reageren op anti-VEGF therapie
Completed
- Conditions
- neovascular age-related macular degeneration, natte leeftijdsgebonden maculadegeneratie
- Registration Number
- NL-OMON19994
- Lead Sponsor
- Prof. Dr. C.B. HoyngRadboud University Nijmegen Medical Centre, Ophthalmology Department
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Patients with inadequate response to prior anti-VEGF treatment defined as a persistent central retinal thickness (CRT) of ¡Ý300 ¦Ìm combined with a response of no greater than a reduction of 50 ¦Ìm in CRT on OCT after each previous intravitreal anti-VEGF treatment.
- Patients will have received at least 6 anti-VEGF injections within 1 year.
Exclusion Criteria
- Signs of subretinal fibrosis, scarring or geographic atrophy on OCT or FA, involving the center of the macula.
- Pigment epithelial detachment with a height of ¡Ý150¦Ìm.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in central retinal thickness as measured on OCT between inclusion and one month after 3 monthly aflibercept injections
- Secondary Outcome Measures
Name Time Method - Change in visual acuity between inclusion and one month after 3 monthly aflibercept injections.<br /><br>- Number of patients responding to aflibercept defined as a decrease in CRT of >50¦Ìm from inclusion compared to visit 5. <br /><br>- Number of patients gaining >5 letters of vision from inclusion compared to visit 5.